Literature DB >> 12656653

Barrett's oesophagus: optimal strategies for prevention and treatment.

Ronnie Fass1, Richard E Sampliner.   

Abstract

Barrett's oesophagus is a change in the lining of the distal oesophagus recognised at endoscopy and documented to have intestinal metaplasia by biopsy. It is thought that it is an acquired condition resulting from chronic gastro-oesophageal reflux disease (GORD). Barrett's oesophagus has the potential to progress to adenocarcinoma of the oesophagus. Evidence to support the association between Barrett's oesophagus and GORD appears to be strong but circumstantial. The intermediate steps that lead from GORD to Barrett's oesophagus are speculative and the timeline for the development of this condition remains obscure. It has yet to be demonstrated that erosive oesophagitis is a necessary intermediate step for the development of Barrett's oesophagus. In spite of effective therapy, documentation that medical or surgical therapy prevents Barrett's oesophagus is lacking. The goal of screening for Barrett's oesophagus is ultimately to improve the survival of patients with adenocarcinoma of the oesophagus. This goal has not been achieved and the evidence-based criteria for screening remain to be defined. Medical and surgical therapy of Barrett's oesophagus is effective in controlling reflux, although not proven to prevent neoplastic progression of the at risk mucosa. Endoscopic techniques of mucosal injury have been applied as alternatives to oesophagectomy in efforts to prevent progression to cancer. Surveillance endoscopy and biopsy is the currently accepted method aimed at early intervention and improved survival for oesophageal adenocarcinoma. A working surveillance protocol to accomplish this is proposed based on dysplasia grade. If no dysplasia is found and confirmed with subsequent endoscopy and biopsy, a 3-year interval is recommended. If only low grade dysplasia is confirmed, then annual endoscopy until no dysplasia is recognised is recommended. On the basis of defined risk factors, high grade dysplasia can lead to intense surveillance every 3 months or an intervention. Future developments in understanding the biology of Barrett's oesophagus and in therapeutic interventions will provide an opportunity for more effective screening, surveillance and prevention of neoplastic progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12656653     DOI: 10.2165/00003495-200363060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  92 in total

1.  Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?

Authors:  A Soni; R E Sampliner; A Sonnenberg
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

2.  Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression.

Authors:  B J Kovacs; Y K Chen; T D Lewis; L J DeGuzman; K S Thompson
Journal:  Gastrointest Endosc       Date:  1999-05       Impact factor: 9.427

3.  Familial Barrett's oesophagus?

Authors:  A Prior; P J Whorwell
Journal:  Hepatogastroenterology       Date:  1986-04

4.  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Authors:  A P Weston; A S Badr; R S Hassanein
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

5.  The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure.

Authors:  S Oberg; T R DeMeester; J H Peters; J A Hagen; J J Nigro; S R DeMeester; J Theisen; G M Campos; P F Crookes
Journal:  J Thorac Cardiovasc Surg       Date:  1999-03       Impact factor: 5.209

6.  Correlation of oesophageal acid exposure with Barrett's oesophagus length.

Authors:  R Fass; R W Hell; H S Garewal; P Martinez; G Pulliam; C Wendel; R E Sampliner
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

7.  The gastroesophageal flap valve: in vitro and in vivo observations.

Authors:  L D Hill; R A Kozarek; S J Kraemer; R W Aye; C D Mercer; D E Low; C E Pope
Journal:  Gastrointest Endosc       Date:  1996-11       Impact factor: 9.427

8.  Esophageal acid sensitivity in Barrett's esophagus.

Authors:  D A Johnson; C Winters; T J Spurling; S J Chobanian; E L Cattau
Journal:  J Clin Gastroenterol       Date:  1987-02       Impact factor: 3.062

9.  Barrett's oesophagus: effect of antireflux surgery on symptom control and development of complications.

Authors:  S E Attwood; A P Barlow; T L Norris; A Watson
Journal:  Br J Surg       Date:  1992-10       Impact factor: 6.939

10.  Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus.

Authors:  D A Katzka; D O Castell
Journal:  Am J Gastroenterol       Date:  1994-07       Impact factor: 10.864

View more
  4 in total

Review 1.  Chemokines and their receptors in esophageal cancer--the systematic review and future perspectives.

Authors:  Marta Łukaszewicz-Zając; Barbara Mroczko; Maciej Szmitkowski
Journal:  Tumour Biol       Date:  2015-07-01

2.  The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled?

Authors:  Emmanouela Tsoukali; Daniel Sifrim
Journal:  J Neurogastroenterol Motil       Date:  2010-07-27       Impact factor: 4.924

Review 3.  The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review.

Authors:  Eugene Y Chang; Cynthia D Morris; Ann K Seltman; Robert W O'Rourke; Benjamin K Chan; John G Hunter; Blair A Jobe
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

Review 4.  Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2018-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.